|Composition :||100mg, 200 mg|
|Indications :||Pharyngitis, tonsillitis, sinusitis, otitis media, pneumonias, acute exacerbations of chronic bronchitis, staphylococcal and streptococcal skin and soft tissue infections, chlamydial pulmonary and genital infections and gonorrhoea. Prophylaxis and treatment of MAC infection in AIDS patients. Other uses like typhoid, toxoplasmosis and malaria are being explored.|
|Safety Profile :||It is comparatively newer antibiotics|
|Adverse Effects :||Mild gastric upset, abdominal pain, headache, dizziness etc.|
|Drug Interactions :||No interaction with hepatic cytochrome P450 enzyme|
|Dosage :||500mg OD orally, URTI/LRTI, skin & soft tissue infections: 500mg OD followed by 250mg OD |
Children :10mg/kg/day for 3 days
|Composition :||250mg,500mg,1gm,2 gm|
Each vial contains following:
Antibiotics and Anti Inefectives
Chromatographic Purity - NLT 99.5%
Pack Size: 2ml,30 ml vial.
20mg/2ml, 40mg/1ml, 80mg/2ml, 400mg/10ml,1200mg/30ml
Potent antibiotic having a broader spectrum of action against a wide variety of bacterial infections.
Valuable in critically ill patients, with impaired host defence, burns, urinary tract infections, lung abscesses, osteomyelitis, middle ear infection, septicaemia, meningitis caused by gram negative bacilli.
3-5 mg/kg body wt IM or IV daily in 3 divided doses for 7 to 10 days, 25-50 mg/kg/day
Uraemia, severe renal function impairment; pregnancy, neonatals (except in life threatening situations)
Dose of gentamicin must be precisely calculated according to body wt and level of renal function.
Reduced dose necessary.
Reduced dose may be necessary due to adverse effects.
Irreversible ototoxicity, nephrotoxicity headache, rashes, thrombocytopenia and joint pain.
Drug Interactions :
Increased incidence of toxicity when combined with ethacrynic acid, risk of loss of hearing/kidney failure. Cephalosporins, hydrocortisone & indomethacin potentiate nephrotoxicity, neuro-muscular blocking agents.
|Composition :||100mg/ ml (100ml pack)|
|Indications :||Treatment of partial onset seizures in adults with epilepsy.|
|Contraindications :||Hypersensitivitiy to levetiracetam or other pyrrolidone derivatives.|
|Safety Profile :||Should be withdrawn gradually to minimize the potential of increased seizure frequency. |
Caution required in patient with moderate and severe renal impairment and patients undergoing hemodialysis. Assessment of renal function is recommended before selection. Driving or operating machinery is not recommended.
|Adverse Effects :||Headache, anxiety, depression, dizziness, somnolence, increase cough, convulsion, vertigo, hallycination, irritability psychotic disorder, thromobocytopenia, neutropenia, leukopenia.|
|Drug Interactions:||It does not influence the plasma concentration of existing AEDs (like phenytoin)and these AEDs do not influence the pharma cokinetics of levetiracetam.|
|Dosage :||Intial dose 1000 mg / day B.I.D depending upon the tolerance and response. Incremental dose is 1000 mg day additional every 2 weeks. |
Maximum doses 3000 mg / day.
Dose should be withdraw gradually e.g . 500 mg twice daily decrements every 2-4 weeks.
|Purity :||Not less than 99%.|